Back to Search
Start Over
Cytokinetics just downgraded at Goldman Sachs, here's why
- Source :
- The Fly. August 13, 2024
- Publication Year :
- 2024
-
Abstract
- Goldman Sachs downgraded Cytokinetics to Neutral from Buy with a price target of $60, down from $85. With the the company's financing overhang removed, investor focus turns to upcoming regulatory [...]
- Subjects :
- The Goldman Sachs Group Inc.
Risk assessment
Business
News, opinion and commentary
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.804659401